Clinical Studies on Roxithromycin Treatment of Chronic Sinusitis

Autor:	Makoto Kosai, Ikuji Kawata, Shuji Okada, Junji Koda, Mikio Yamaguchi, Yasuo Ishitani, Yohji Hori, Koichiro Sakamaki, Hiroyuki Hiramoto, Akio Kondo, Takaaki Shimada, Yasuo Koike, Shin-ya Ohtsu, Tatsuya Ishida, Naoya Takeda, Atsushi Mabuchi, Kuniharu Agawa, Ritsuko Abe
Rok vydání:	1994
Předmět:	medicine.medical_specialty business.industry Roxithromycin Chronic sinusitis medicine.disease Surgery Otorhinolaryngology Internal medicine Long period medicine Paranasal sinusitis Clinical efficacy business Sinusitis medicine.drug
Zdroj:	Practica Oto-Rhino-Laryngologica. 87:569-578
ISSN:	1884-4545 0032-6313
DOI:	10.5631/jibirin.87.569
Popis:	Roxithromycin (RXM) was administered to 191 patients with chronic paranasal sinusitis. The overall rate of excellent and good clinical response was 58.1% as judged by the attending otolaryngologists and 56.0% as judged by the committee.In bacteriological examinations performed on 39 patients before administration 52 organisms were isolated, and 25 (83.3%) of the 30 cultures examined showed sensitivities to RXM. Among patients infected with sensitive organisms the clinical efficacy rate (CER) was 81.0%.X-ray examinations were performed on 59 patients with an CER of 66.1%. The rates for excellent and good results were 75.9% for maxillary sinusitis and 78.3% for ethmoid sinusitis.Side effects, in the form of mild digestive symptoms, were noted in only 3 patients (1.6%), but no treatment was required even though RXM was administered for a long period of time, up to 178 days.These results indicate that RXM is effective in the treatment of chronic paranasal sinusitis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bbadcbf4ebb36d7811027eaafe46ee1e https://doi.org/10.5631/jibirin.87.569 Zobrazit plný text záznamu